AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional ...

Johnson & Johnson (NYSE:JNJ) Q4 2025 Earnings Call Transcript January 21, 2026 Johnson & Johnson reports earnings inline with ...

These stocks offer impressive long-term upside with downside protection.

Extracting therapeutic antibodies from biological systems requires stringent purification processes. To reduce costs and accelerate development, novel strategies are essential ...

CVS Health® today announced key milestones in its ongoing effort to make health care simpler and more affordable for American ...